Our previous data demonstrated that nucleolin expression at the cell surface increases with the GBM malignancy grade, thus indicating that it constitutes a useful histopathological marker for glioblastoma grading, as well as, for targeted therapy approaches (Galzio et al., 2012; Dhez et al., 2018). Here, NUCLEOLIN is linked to glioblastoma.